These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33407715)

  • 21. A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer.
    Yuan M; Chen T; Jin L; Zhang P; Xie L; Zhou S; Fan L; Wang L; Zhang C; Tang N; Guo L; Xie C; Duo Y; Li L; Shi L
    J Nanobiotechnology; 2023 Oct; 21(1):393. PubMed ID: 37898773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation.
    Muvaffak A; Coleman KG
    Front Oncol; 2024; 14():1380633. PubMed ID: 38807759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
    Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
    Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
    Rimel BJ; Dockery L; Randall LM; Moore K
    Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
    Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
    Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
    Frerker B; Bock F; Cappel ML; Kriesen S; Klautke G; Hildebrandt G; Manda K
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
    Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.
    De Santis M; Breijo SM; Robinson P; Capone C; Pascoe K; Van Sanden S; Hashim M; Trevisan M; Daly C; Reitsma F; van Beekhuizen S; Ruan H; Heeg B; Verzoni E
    Adv Ther; 2024 Aug; 41(8):3039-3058. PubMed ID: 38958846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
    Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
    Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
    Davidson D; Wang Y; Aloyz R; Panasci L
    Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
    Tsang ES; Dhawan MS; Pacaud R; Thomas S; Grabowsky J; Wilch L; Karipineni S; Kelley RK; Ko AH; Collisson E; Chapman JS; Ueda S; Bergsland EK; Munster P
    JCO Precis Oncol; 2024 Jun; 8():e2300494. PubMed ID: 38865673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
    Jones P; Wilcoxen K; Rowley M; Toniatti C
    J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer.
    Chang J; Quan S; Tian S; Wang S; Li S; Guo Y; Yang T; Yang X
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):304. PubMed ID: 38869633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
    Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A
    EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.